Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strides' New CEO Reiterates Strategy, Thrust On Execution

Q3 Revenues Up 29% Led By US, UK

Executive Summary

Newly-appointed CEO at Strides, R Ananthanarayanan, sees no reason to change course as current strategy continues yielding positive results. Company posts 29% increase in third-quarter revenues on the back of 62% growth in the US

You may also be interested in...



Strides’ New CEO Is Former Cipla COO

Arun Kumar is stepping down as chief executive of Strides Pharma to focus on overall corporate strategy and the company’s return to injectables. He will be replaced by former Cipla chief operating officer R Ananthanarayanan.

Strides Injectables Re-Entry Shifts Into High Gear

Strides Pharma Science, which has reported a strong second-quarter performance, said its reborn injectables business will “be full-blown” in several markets by December thanks to the expiry of a non-compete agreement with Mylan.

More Recalls Seen For Ranitidine

Sandoz is voluntarily recalling all ranitidine hydrochloride capsules in the US because of “confirmed’ NDMA contamination, while Dr Reddy’s is suspending global shipments of the generic version of Zantac due to worries about the presence of the suspected cancer-causing agent in its products, as suppliers around the world grapple with the issue.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141573

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel